Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antineoplastic agent
immunosuppressant |
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01AA01
|
| gptkbp:blackBoxWarning |
myelosuppression
bladder toxicity secondary malignancies |
| gptkbp:brand |
gptkb:Cytoxan
gptkb:Endoxan gptkb:Procytox |
| gptkbp:CASNumber |
50-18-0
|
| gptkbp:chemicalFormula |
C7H15Cl2N2O2P
|
| gptkbp:contraindication |
active infections
severe bone marrow suppression hypersensitivity to cyclophosphamide |
| gptkbp:discoveredBy |
gptkb:Arnold_Holtzman
gptkb:Norbert_Brock |
| gptkbp:discoveredIn |
1958
|
| gptkbp:excretion |
kidneys
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cyclophosphamide
|
| gptkbp:interactsWith |
gptkb:warfarin
allopurinol phenobarbital live vaccines |
| gptkbp:KEGGID |
D00210
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antineoplastic agent
DNA crosslinking |
| gptkbp:MedlinePlusID |
a682080
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
261.1 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
2907
CHEMBL54 DB00531 |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
vomiting hair loss infertility bone marrow suppression increased risk of infection hemorrhagic cystitis |
| gptkbp:UNII |
8N3DW7272P
|
| gptkbp:usedFor |
gptkb:cancer
multiple sclerosis autoimmune diseases lupus rheumatoid arthritis nephrotic syndrome |
| gptkbp:WHOModelListOfEssentialMedicines |
true
|
| gptkbp:bfsParent |
gptkb:CTX
|
| gptkbp:bfsLayer |
6
|